Abetimus: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| (One intermediate revision by the same user not shown) | |||
| Line 3: | Line 3: | ||
| verifiedfields = changed | | verifiedfields = changed | ||
| verifiedrevid = 477002123 | | verifiedrevid = 477002123 | ||
| image = Abetimus.svg | | image = Abetimus.svg | ||
| image2 = | |||
| width = 200px | | width = 200px | ||
}} | }} | ||
'''Abetimus''' is a synthetic [[ | '''Abetimus''' is a synthetic [[immunosuppressive drug]] designed for the treatment of [[systemic lupus erythematosus]] (SLE), an [[autoimmune disease]] characterized by the body's immune system attacking its own tissues. Abetimus is specifically engineered to reduce the production of [[anti-double-stranded DNA antibodies]], which are implicated in the pathogenesis of SLE. | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Abetimus functions by | Abetimus functions by mimicking the structure of [[double-stranded DNA]] (dsDNA), thereby acting as a decoy for the [[B cells]] that produce anti-dsDNA antibodies. By binding to these B cells, abetimus prevents them from producing harmful antibodies that can lead to tissue damage in patients with SLE. This mechanism helps in reducing the [[inflammatory response]] and subsequent [[organ damage]] associated with the disease. | ||
==Clinical Use== | ==Clinical Use== | ||
Abetimus is used | Abetimus is primarily used in patients with SLE who have high levels of anti-dsDNA antibodies. It is administered as part of a comprehensive treatment plan that may include other [[immunosuppressants]], [[corticosteroids]], and [[antimalarial drugs]] like [[hydroxychloroquine]]. The goal of treatment with abetimus is to achieve [[disease remission]] and prevent [[flare-ups]] of SLE symptoms. | ||
==Side Effects== | |||
Common side effects of abetimus include [[injection site reactions]], such as redness and swelling, as well as [[flu-like symptoms]] such as fever and fatigue. More serious side effects can include [[allergic reactions]] and increased risk of [[infections]] due to its immunosuppressive action. | |||
==Development and Approval== | ==Development and Approval== | ||
Abetimus was developed as a novel approach to | Abetimus was developed as a novel approach to specifically target the pathogenic antibodies in SLE. Its development involved extensive [[clinical trials]] to assess its efficacy and safety. However, its approval status may vary by country, and it is important for healthcare providers to consider the latest guidelines and research when prescribing this medication. | ||
==Related pages== | ==Related pages== | ||
* [[Systemic lupus erythematosus]] | * [[Systemic lupus erythematosus]] | ||
* [[Immunosuppressive drug]] | |||
* [[Autoimmune disease]] | * [[Autoimmune disease]] | ||
* [[ | * [[B cell]] | ||
* [[Antibody]] | * [[Antibody]] | ||
[[Category:Immunosuppressants]] | |||
[[Category:Autoimmune diseases]] | |||
<gallery> | <gallery> | ||
File:Abetimus.svg| | File:Abetimus.svg|Abetimus | ||
</gallery> | </gallery> | ||
Latest revision as of 00:37, 20 February 2025
A synthetic drug used in the treatment of systemic lupus erythematosus
| Abetimus | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Abetimus is a synthetic immunosuppressive drug designed for the treatment of systemic lupus erythematosus (SLE), an autoimmune disease characterized by the body's immune system attacking its own tissues. Abetimus is specifically engineered to reduce the production of anti-double-stranded DNA antibodies, which are implicated in the pathogenesis of SLE.
Mechanism of Action[edit]
Abetimus functions by mimicking the structure of double-stranded DNA (dsDNA), thereby acting as a decoy for the B cells that produce anti-dsDNA antibodies. By binding to these B cells, abetimus prevents them from producing harmful antibodies that can lead to tissue damage in patients with SLE. This mechanism helps in reducing the inflammatory response and subsequent organ damage associated with the disease.
Clinical Use[edit]
Abetimus is primarily used in patients with SLE who have high levels of anti-dsDNA antibodies. It is administered as part of a comprehensive treatment plan that may include other immunosuppressants, corticosteroids, and antimalarial drugs like hydroxychloroquine. The goal of treatment with abetimus is to achieve disease remission and prevent flare-ups of SLE symptoms.
Side Effects[edit]
Common side effects of abetimus include injection site reactions, such as redness and swelling, as well as flu-like symptoms such as fever and fatigue. More serious side effects can include allergic reactions and increased risk of infections due to its immunosuppressive action.
Development and Approval[edit]
Abetimus was developed as a novel approach to specifically target the pathogenic antibodies in SLE. Its development involved extensive clinical trials to assess its efficacy and safety. However, its approval status may vary by country, and it is important for healthcare providers to consider the latest guidelines and research when prescribing this medication.
Related pages[edit]
-
Abetimus
